US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Lakewood-Amedex Biotherapeutics (Direct Listing)

0.9502

-0.5498-36.65%

Pre-market: 0.8001-0.1501-15.80%08:42 EDT

Volume:37.88M

Turnover:87.11M

Market Cap:13.61M

PE:-3.47

High:1.47

Open:1.35

Low:0.9200

Close:1.50

52wk High:9.82

52wk Low:0.9200

Shares:14.32M

Float Shares:4.70M

Volume Ratio:167.62

T/O Rate:805.97%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.2740

ROE:--

ROA:-303.80%

PB:-6.92

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Lakewood-Amedex advances Nu-3 gel toward Phase 2 trial in infected diabetic foot ulcers

Lakewood-Amedex Biotherapeutics Announces Positive Data for the Advancement of Lead Candidate, Nu-3, in Infected Diabetic Foot Ulcers

THOMSON REUTERS

Lakewood-Amedex Biotherapeutics : Key Formulation, Delivery and Manufacturing Steps Completed in Preparation for Planned Phase 2 Clinical Trial

THOMSON REUTERS

Lakewood-Amedex taps PERI as CRO for Nu-3 Phase 2 diabetic foot ulcer trial

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/LABT"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LABT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABT\",,,,,undefined,":{"symbol":"LABT","market":"US","secType":"STK","nameCN":"Lakewood-Amedex Biotherapeutics (Direct Listing)","latestPrice":0.9502,"timestamp":1779134400000,"preClose":1.5,"halted":0,"volume":37880443,"hourTrading":{"tag":"盘前","latestPrice":0.8001,"preClose":0.9502,"latestTime":"08:42 EDT","volume":158343,"amount":132712.96231428,"timestamp":1779194575078,"change":-0.1501,"changeRate":-0.157967,"amplitude":0.217428},"delay":0,"changeRate":-0.3665333333333333,"floatShares":4700000,"shares":14320400,"eps":-0.274,"marketStatus":"Pre-Mkt","change":-0.5498,"latestTime":"05-19 08:43:11 EDT","open":1.35,"high":1.47,"low":0.92,"amount":87106627.94492349,"amplitude":0.366667,"askPrice":0.9118,"askSize":100,"bidPrice":0.782,"bidSize":263,"shortable":0,"etf":0,"ttmEps":-0.274,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1779197400000},"marketStatusCode":1,"adr":0,"listingDate":1776916800000,"exchange":"NASDAQ","adjPreClose":0.9502,"preHourTrading":{"tag":"盘前","latestPrice":0.8001,"preClose":0.9502,"latestTime":"08:42 EDT","volume":158343,"amount":132712.96231428,"timestamp":1779194575078,"change":-0.1501,"changeRate":-0.157967,"amplitude":0.217428},"postHourTrading":{"tag":"盘后","latestPrice":0.8911,"preClose":0.9502,"latestTime":"19:59 EDT","volume":744205,"amount":666843.821107,"timestamp":1779148782671,"change":-0.0591,"changeRate":-0.062197,"amplitude":0.131446},"volumeRatio":167.61678151384643},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABT\",,,,,undefined,":{"symbol":"LABT","floatShares":4700000,"roa":"-303.80%","roe":"--","lyrEps":0,"volumeRatio":167.61678151384643,"shares":14320400,"dividePrice":0,"high":1.47,"amplitude":0.366667,"preClose":1.5,"low":0.92,"week52Low":0.92,"pbRate":"-6.92","week52High":9.82,"institutionHeld":0,"latestPrice":0.9502,"committee":0.449036,"eps":-0.274,"divideRate":0,"volume":37880443,"delay":0,"ttmEps":-0.274,"open":1.35,"prevYearClose":8,"prevWeekClose":1.5,"prevMonthClose":2.66,"prevQuarterClose":8,"fiveDayClose":3.16},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LABT\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LABT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LABT\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LABT\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LABT","date":"2026-05-15","current":-3.467883,"percent":1,"low":-12.282138,"twenty":-12.043939,"median":-11.649421,"eighty":-11.314454,"high":-7.294845,"avg":-11.240017,"sd":1.440936,"marketCap":28067917},"quantilePoints":[{"date":"2026-05-08","current":-12.282138,"twenty":-12.192813,"median":-11.891342,"eighty":-11.604759,"marketCap":47257207},{"date":"2026-05-15","current":-7.294845,"twenty":-12.043939,"median":-11.649421,"eighty":-11.314454,"marketCap":28067917}],"updateTime":1779153473972},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LABT\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2636807358","title":"Lakewood-Amedex advances Nu-3 gel toward Phase 2 trial in infected diabetic foot ulcers","url":"https://stock-news.laohu8.com/highlight/detail?id=2636807358","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636807358?lang=en_us&edition=fundamental","pubTime":"2026-05-18 20:05","pubTimestamp":1779105903,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics reported positive development data for its lead candidate Nu-3 as it moves toward a planned Phase 2 trial in mildly infected diabetic foot ulcers.The update covered completed formulation, delivery, and cGMP manufacturing work intended to support clinical supply for the Phase 2 program.Stability and product-quality testing indicated the drug substance and gel formulation remained usable over extended storage periods, supporting trial readiness.The company positioned Nu-3 as a topical antimicrobial designed to lower the risk of resistance, with broader potential across other infectious-disease settings.Results have already been presented in this announcement, with the Phase 2 trial expected to be run in the future.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nNDLbv4Y9v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636078054","title":"Lakewood-Amedex Biotherapeutics Announces Positive Data for the Advancement of Lead Candidate, Nu-3, in Infected Diabetic Foot Ulcers","url":"https://stock-news.laohu8.com/highlight/detail?id=2636078054","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636078054?lang=en_us&edition=fundamental","pubTime":"2026-05-18 20:02","pubTimestamp":1779105770,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nFWN41V0SJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636073393","title":"Lakewood-Amedex Biotherapeutics : Key Formulation, Delivery and Manufacturing Steps Completed in Preparation for Planned Phase 2 Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2636073393","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636073393?lang=en_us&edition=fundamental","pubTime":"2026-05-18 20:02","pubTimestamp":1779105770,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nFWN41V0SJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634216060","title":"Lakewood-Amedex taps PERI as CRO for Nu-3 Phase 2 diabetic foot ulcer trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2634216060","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634216060?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:04","pubTimestamp":1778587484,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics entered agreement with Professional Education and Research Institute  to act as contract research organization for upcoming Phase 2 clinical program of Nu-3 in mildly infected diabetic foot ulcers.Partnership targets Phase 2a single-blinded study comparing 2%, 5%, 10% Nu-3 gel concentrations, followed by Phase 2b testing once-daily or twice-daily dosing versus placebo.Collaboration positions PERI’s wound-care investigator network to support site access, patient recruitment, data generation as Nu-3 advances toward potential registration pathway.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL9Dx8T7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABT"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":4,"pageCount":1,"totalSize":16,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/LABT\",params:#limit:6,delay:false,,,undefined,":[]}}